Haemonetics (STU:HAZ) Tariff Resilience Score: 6/10 (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:HAZ Haemonetics Corp STU:HAZ
87 GF Score
Price €67.50
GF Value €74.79
! 5 Warning Signs
View Full Analysis

What is Haemonetics Tariff Resilience Score?

Haemonetics STU:HAZ +1.50% 87 Tariff Resilience Score is 6 as of Jul. 14, 2026. GuruFocus rates STU:HAZ with a GF Score™ of 87/100 and a GF Value™ of €74.79. The stock has 5 warning signs investors should review. Among 835 Medical Devices & Instruments companies, Haemonetics ranks better than 91.02% on this metric.

Haemonetics has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Haemonetics has Haemonetics Corp has moderate tariff exposure due to its global supply chain for medical devices. It has manufacturing in multiple countries, which helps mitigate risks. Historical tariff changes have had some impact, but the company has alternative suppliers and some pricing power to manage costs.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Haemonetics might have Average Resilient.

Haemonetics  (STU:HAZ) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Haemonetics Tariff Resilience Score Related Terms

STU:HAZ vs ITGR, IRTC, ESTA: Tariff Resilience Score Comparison

For the Medical Devices subindustry, Haemonetics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Haemonetics Tariff Resilience Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Haemonetics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Haemonetics's Tariff Resilience Score falls into.


STU:HAZ
87GF Score
Haemonetics Corp STU:HAZ
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Haemonetics (STU:HAZ) has a Tariff Resilience Score of 6 as of Jul. 14, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Haemonetics ranks #75 out of 835 companies in the Medical Devices & Instruments industry, placing it in the top 9%.
Is Haemonetics' Tariff Resilience Score too high?
Haemonetics' current Tariff Resilience Score is 6. Based on the distribution chart, Haemonetics ranks #75 out of 835 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Haemonetics has a GF Score™ of 87/100, reflecting its overall financial health beyond just this single metric.
How does Haemonetics' Tariff Resilience Score compare to ITGR and IRTC?
According to the Medical Devices & Instruments industry distribution chart, Haemonetics ranks #75 out of 835 companies for Tariff Resilience Score. This places Haemonetics in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Medical Devices & Instruments company?
A good Tariff Resilience Score depends on the Medical Devices & Instruments industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Haemonetics's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haemonetics stock overvalued right now?
Haemonetics (STU:HAZ) has a current Tariff Resilience Score of 6. The stock's GF Value™ is €74.79, compared to a current price of €67.50 — trading 9.7% below its estimated fair value. The current Tariff Resilience Score is 6. Haemonetics' overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Haemonetics (STU:HAZ), the current Tariff Resilience Score is 6 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Haemonetics (STU:HAZ) Overvalued in 2026?

Based on GuruFocus' analysis, Haemonetics stock appears to be undervalued. The current stock price of €67.50 is trading 9.7% below its estimated GF Value™ of €74.79.

Key valuation signals for STU:HAZ:

  • Tariff Resilience Score: 6
  • GF Value™: €74.79 vs. price of €67.50 (9.7% below fair value)
  • GF Score™: 87/100 with 5 warning signs

No single metric tells the full story. See the STU:HAZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Haemonetics Business Description

Other Exchanges HAE:USA
Address 125 Summer Street, Boston, MA, USA, 02110
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
87GF Score

Get the complete analysis for STU:HAZ

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€67.50
Price
€74.79
GF Value